- Home
- FENC vs GEVO Comparison
FENC vs GEVO Comparison
Compare FENC & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- GEVO
- Stock Information
- Founded
- FENC 1996
- GEVO 2005
- Country
- FENC United States
- GEVO United States
- Employees
- FENC 32
- GEVO N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- GEVO Major Chemicals
- Sector
- FENC Health Care
- GEVO Industrials
- Exchange
- FENC Nasdaq
- GEVO Nasdaq
- Market Cap
- FENC 222.9M
- GEVO 246.8M
- IPO Year
- FENC 2001
- GEVO 2011
- Fundamental
- Price
- FENC $8.34
- GEVO $1.32
- Analyst Decision
- FENC Strong Buy
- GEVO Buy
- Analyst Count
- FENC 2
- GEVO 2
- Target Price
- FENC $13.00
- GEVO $7.58
- AVG Volume (30 Days)
- FENC 83.2K
- GEVO 5.1M
- Earning Date
- FENC 08-12-2025
- GEVO 08-07-2025
- Dividend Yield
- FENC N/A
- GEVO N/A
- EPS Growth
- FENC N/A
- GEVO N/A
- EPS
- FENC N/A
- GEVO N/A
- Revenue
- FENC $30,912,000.00
- GEVO $42,034,000.00
- Revenue This Year
- FENC $0.85
- GEVO $1,022.79
- Revenue Next Year
- FENC $55.16
- GEVO $12.26
- P/E Ratio
- FENC N/A
- GEVO N/A
- Revenue Growth
- FENC N/A
- GEVO 145.38
- 52 Week Low
- FENC $3.96
- GEVO $0.48
- 52 Week High
- FENC $8.72
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- FENC 58.31
- GEVO 55.45
- Support Level
- FENC $7.53
- GEVO $1.17
- Resistance Level
- FENC $8.68
- GEVO $1.41
- Average True Range (ATR)
- FENC 0.49
- GEVO 0.09
- MACD
- FENC -0.04
- GEVO 0.00
- Stochastic Oscillator
- FENC 63.18
- GEVO 62.50
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.